Literature DB >> 10489968

Radionuclide therapy.

J F Chatal1, C A Hoefnagel.   

Abstract

Nuclear medicine therapy uses unsealed radioactive sources for the selective delivery of radiation to tumours or target organs. For benign disorders such as thyrotoxicosis and arthritis radionuclide therapy provides an alternative to surgery or medical treatment. In cancer treatment, it often combines the advantage of target selectivity (like brachytherapy or external beam radiotherapy) with that of being systemic, as with chemotherapy, and it may be used as part of a therapeutic strategy with curative intent or for disease control and palliation. Toxicity is generally limited to the haematopoietic tissue and few side-effects are observed. When cure is feasible, the long-term consequences of radionuclide therapy (eg, fertility disorders and leukaemia or other secondary cancers) do compare favourably with the risks associated with and accepted for chemotherapy and radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10489968     DOI: 10.1016/S0140-6736(99)06002-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.

Authors:  Shuang Liu
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

2.  Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide.

Authors:  J Tyler French; Beth Goins; Marcela Saenz; Shihong Li; Xavier Garcia-Rojas; William T Phillips; Randal A Otto; Ande Bao
Journal:  J Vasc Interv Radiol       Date:  2010-05-15       Impact factor: 3.464

Review 3.  Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches.

Authors:  Makoto Hosono
Journal:  Nucl Med Mol Imaging       Date:  2019-01-29

4.  Genotoxicity Associated with 131I and 99mTc Exposure in Nuclear Medicine Staff: A Physical and Biological Monitoring Study.

Authors:  Justyna Miszczyk; Aleksander Gałaś; Agnieszka Panek; Aldona Kowalska; Magdalena Kostkiewicz; Eliza Borkowska; Kamil Brudecki
Journal:  Cells       Date:  2022-05-16       Impact factor: 7.666

5.  The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand.

Authors:  Imed Salhi; Sylvie Cambon-Roques; Isabelle Lamarre; Daniel Laune; Franck Molina; Martine Pugnière; Didier Pourquier; Marian Gutowski; Jean-Yves Picard; Françoise Xavier; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

6.  Radioiodine-induced kidney damage and protective effect of amifostine: An experimental study.

Authors:  T Aktoz; G Durmus-Altun; U Usta; N Torun; A Ergulen; I H Atakan
Journal:  Hippokratia       Date:  2012-01       Impact factor: 0.471

7.  Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model.

Authors:  Yasuhiro Ohshima; Hitomi Sudo; Shigeki Watanabe; Kotaro Nagatsu; Atsushi B Tsuji; Tetsuya Sakashita; Yoichi M Ito; Keiichiro Yoshinaga; Tatsuya Higashi; Noriko S Ishioka
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-19       Impact factor: 9.236

8.  Antibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer models.

Authors:  Aurélie Rondon; Nancy Ty; Jean-Baptiste Bequignat; Mercedes Quintana; Arnaud Briat; Tiffany Witkowski; Bernadette Bouchon; Claude Boucheix; Elisabeth Miot-Noirault; Jean-Pierre Pouget; Jean-Michel Chezal; Isabelle Navarro-Teulon; Emmanuel Moreau; Françoise Degoul
Journal:  Sci Rep       Date:  2017-11-02       Impact factor: 4.379

9.  Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers.

Authors:  Véronique Garambois; Fabienne Glaussel; Elodie Foulquier; Marc Ychou; Martine Pugnière; Robin X Luo; Binyam Bezabeh; André Pèlegrin
Journal:  BMC Cancer       Date:  2004-10-15       Impact factor: 4.430

Review 10.  Molecular imaging of oncolytic viral therapy.

Authors:  Dana Haddad; Yuman Fong
Journal:  Mol Ther Oncolytics       Date:  2015-02-04       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.